Medizin - Open Access .click

Results 91 to 100 of about 27,270 (200)

Ut aliquid fieri videatur: „Um es so aussehen zu lassen, es werde etwas getan“

Babylonia
Eines haben Medizin und Politik, zumal Bildungsund Schulpolitik oft gemeinsam, sie setzen beide gerne und manchmal auch durchaus erfolgreich auf Fiktionen.
Rudolf Künzli
doaj

Efficacy of a Decision‐Making Aid About Homeopathy in Patients With Cancer: A Single‐Arm, Pre–Post Observational Study

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Despite lacking evidence, homeopathy continues to enjoy high levels of usage and general acceptance. Particularly concerning the treatment of cancer, this can pose risks, especially when it leads to delay or replacement of evidence‐based treatments.
Maximilian Gimbel +8 more
wiley +1 more source

Self-help management of side effects in female cancer patients -analysis of the forum of the Women’s Self-help Association against cancer

BMC Cancer
Background Side effects of cancer treatment have a high impact on patients. Besides physicians and nurses, other patients are an important partner for communication on side effects.
Louisa Schäfer, Lena Josfeld, Jutta Hübner +2 more
doaj +1 more source

Modeling Treatment Response in Tuberculosis Early Bactericidal Activity Trials

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
ABSTRACT Culture‐based monitoring of bacterial load is slow and susceptible to missing data, contributing to the length and cost of TB clinical trials. Non‐culture‐based alternatives, like the Tuberculosis Molecular Load Bacterial Assay (TB‐MBLA), could represent a solution.
Mairi C. W. McClean +15 more
wiley +1 more source

Response‐adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort

British Journal of Haematology, Volume 209, Issue 2, Page 524-533, August 2026.
Summary Secondary central nervous system lymphoma (SCNSL) remains a rare but challenging manifestation of aggressive lymphomas, with limited prospective data to guide treatment decisions in the modern therapeutic era. We conducted a multicentre retrospective cohort study of 105 consecutively treated adult patients diagnosed with SCNSL between 2016 and ...
Farina Eigendorff +10 more
wiley +1 more source

Sustained Clinical Improvement in Birch Pollen Allergy After Two Pre‐Seasonal Short Courses of Allergen‐Specific Immunotherapy: A Long‐Term Open‐Label Extension Study

Clinical &Experimental Allergy, Volume 56, Issue 8, Page 893-903, August 2026.
3 years follow‐up study to a DBPC dose‐finding trial investigating subcutaneous immunotherapy with T502 in birch‐pollen induced allergic rhinoconjunctivitis. 154 birch‐pollen allergic adults received short‐course treatment of 10,000 mTU/mL of T502 for 2 years and were observed during the next season without treatment.
Ralph Mösges +15 more
wiley +1 more source

Comparison of Allergic Rhinitis Treatments on Utilities and Quality of Life: A MASK‐air Study

Clinical &Experimental Allergy, Volume 56, Issue 8, Page 904-913, August 2026.
This mHealth study has shown that fixed combinations of intranasal antihistamines and corticosteroids were associated with higher quality of life than oral antihistamines and intranasal antihistamines. Both intranasal corticosteroids and oral antihistamines were associated with higher quality of life than intranasal antihistamines.
Nuno Lourenço‐Silva +27 more
wiley +1 more source

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Olamkicept up to 2400 mg in Healthy Men: Phase I, Randomized, Placebo‐Controlled, and Double‐Blind Trial

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Olamkicept is a first‐in‐class fully human fusion protein that selectively inhibits trans interleukin (IL)‐6 signaling. Previous phase I clinical trials demonstrated that single doses up to 750 mg and multiple doses up to 600 mg were safe and well tolerated in healthy men and women.
Stanislav Ignatenko +7 more
wiley +1 more source

Komplette Lymphknotendissektion versus selektive Lymphknotenexstirpation bei Melanompatienten mit nodaler Makrometastasierung und adjuvanter Systemtherapie

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 8, Page 1052-1062, August 2026.
Zusammenfassung Hintergrund und Zielsetzung Die komplette Lymphknotendissektion (CLND) gilt als Standardbehandlung bei Melanompatienten mit regionalen Lymphknotenmakrometastasen. Es fehlt jedoch an Evidenz bezüglich des chirurgischen Vorgehens im Kontext adjuvanter Systemtherapien.
Kristine E. Mayer +13 more
wiley +1 more source

Triage von Hautläsionen bei Organtransplantationsempfängern mittels Line‐field Confocal Optical Coherence Tomography: Eine retrospektive Klassifizierungsstudie

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 8, Page 1063-1069, August 2026.
Zusammenfassung Hintergrund/Ziele: Empfänger von Organtransplantaten (OTRs) haben ein erhöhtes Risiko für Keratinozytenkarzinome (KC). Dies führt zu einer niedrigeren Schwelle für Biopsien. Die Line‐field Confocal Optical Coherence Tomography (LC‐OCT) ist eine nicht‐invasive Bildgebungstechnik, mit der maligne Hautveränderungen sichtbar gemacht werden ...
Kevin Jacobsen +4 more
wiley +1 more source